Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas.

Freeman AC, Platt SR, Holmes S, Kent M, Robinson K, Howerth E, Eagleson J, Bouras A, Kaluzova M, Hadjipanayis CG.

J Neurooncol. 2018 May;137(3):653-663. doi: 10.1007/s11060-018-2764-1. Epub 2018 Jan 19.

PMID:
29350351
2.

5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins.

Ross JL, Cooper LAD, Kong J, Gutman D, Williams M, Tucker-Burden C, McCrary MR, Bouras A, Kaluzova M, Dunn WD Jr, Duong D, Hadjipanayis CG, Brat DJ.

Sci Rep. 2017 Nov 15;7(1):15593. doi: 10.1038/s41598-017-15849-w.

3.

Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.

Herting CJ, Chen Z, Pitter KL, Szulzewsky F, Kaffes I, Kaluzova M, Park JC, Cimino PJ, Brennan C, Wang B, Hambardzumyan D.

Glia. 2017 Dec;65(12):1914-1926. doi: 10.1002/glia.23203. Epub 2017 Aug 24.

4.

Intraoperative Spectroscopy with Ultrahigh Sensitivity for Image-Guided Surgery of Malignant Brain Tumors.

Kairdolf BA, Bouras A, Kaluzova M, Sharma AK, Wang MD, Hadjipanayis CG, Nie S.

Anal Chem. 2016 Jan 5;88(1):858-67. doi: 10.1021/acs.analchem.5b03453. Epub 2015 Dec 7.

PMID:
26587976
5.

Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.

Bouras A, Kaluzova M, Hadjipanayis CG.

J Neurooncol. 2015 Aug;124(1):13-22. doi: 10.1007/s11060-015-1807-0. Epub 2015 May 17.

6.

Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.

Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG.

Oncotarget. 2015 Apr 20;6(11):8788-806.

7.

Homozygous EXOSC3 mutation c.92G→C, p.G31A is a founder mutation causing severe pontocerebellar hypoplasia type 1 among the Czech Roma.

Schwabova J, Brozkova DS, Petrak B, Mojzisova M, Pavlickova K, Haberlova J, Mrazkova L, Hedvicakova P, Hornofova L, Kaluzova M, Fencl F, Krutova M, Zamecnik J, Seeman P.

J Neurogenet. 2013 Dec;27(4):163-9. doi: 10.3109/01677063.2013.814651. Epub 2013 Jul 25.

PMID:
23883322
8.

Canine model of convection-enhanced delivery of cetuximab-conjugated iron-oxide nanoparticles monitored with magnetic resonance imaging.

Platt S, Nduom E, Kent M, Freeman C, Machaidze R, Kaluzova M, Wang L, Mao H, Hadjipanayis CG.

Clin Neurosurg. 2012;59:107-13. No abstract available.

9.

Nanotechnology applications for glioblastoma.

Nduom EK, Bouras A, Kaluzova M, Hadjipanayis CG.

Neurosurg Clin N Am. 2012 Jul;23(3):439-49. doi: 10.1016/j.nec.2012.04.006. Epub 2012 Jun 14. Review.

10.

Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy.

Wankhede M, Bouras A, Kaluzova M, Hadjipanayis CG.

Expert Rev Clin Pharmacol. 2012 Mar;5(2):173-86. doi: 10.1586/ecp.12.1. Review.

11.

The importance of advanced parental age in the origin of neurofibromatosis type 1.

Snajderova M, Riccardi VM, Petrak B, Zemkova D, Zapletalova J, Mardesic T, Petrakova A, Lanska V, Marikova T, Bendova S, Havlovicova M, Kaluzova M.

Am J Med Genet A. 2012 Mar;158A(3):519-23. doi: 10.1002/ajmg.a.34413. Epub 2012 Feb 2.

PMID:
22302476
12.

EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.

Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, Wu X, Mao H.

Cancer Res. 2010 Aug 1;70(15):6303-12. doi: 10.1158/0008-5472.CAN-10-1022. Epub 2010 Jul 20.

13.

Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

Kaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ.

Biochim Biophys Acta. 2009 Apr;1795(2):162-72. doi: 10.1016/j.bbcan.2009.01.001. Epub 2009 Jan 22. Review.

14.

Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1.

Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P.

Science. 2009 May 1;324(5927):654-7. doi: 10.1126/science.1170803. Epub 2009 Mar 12.

15.

Chromatin remodeling, metabolism and circadian clocks: the interplay of CLOCK and SIRT1.

Grimaldi B, Nakahata Y, Kaluzova M, Masubuchi S, Sassone-Corsi P.

Int J Biochem Cell Biol. 2009 Jan;41(1):81-6. doi: 10.1016/j.biocel.2008.08.035. Epub 2008 Sep 4. Review.

PMID:
18817890
16.

The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control.

Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, Chen D, Guarente LP, Sassone-Corsi P.

Cell. 2008 Jul 25;134(2):329-40. doi: 10.1016/j.cell.2008.07.002.

17.

Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element.

Kaluz S, Kaluzová M, Stanbridge EJ.

Clin Chim Acta. 2008 Sep;395(1-2):6-13. doi: 10.1016/j.cca.2008.05.002. Epub 2008 May 9. Review.

18.

Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1.

Kaluz S, Kaluzová M, Stanbridge EJ.

Blood. 2008 May 15;111(10):5258-9; author reply 5259-61. doi: 10.1182/blood-2008-02-140079. No abstract available.

19.

Chromatin remodeling and circadian control: master regulator CLOCK is an enzyme.

Grimaldi B, Nakahata Y, Sahar S, Kaluzova M, Gauthier D, Pham K, Patel N, Hirayama J, Sassone-Corsi P.

Cold Spring Harb Symp Quant Biol. 2007;72:105-12. doi: 10.1101/sqb.2007.72.049. Review.

PMID:
18419267
20.

Rational design of minimal hypoxia-inducible enhancers.

Kaluz S, Kaluzová M, Stanbridge EJ.

Biochem Biophys Res Commun. 2008 Jun 13;370(4):613-8. doi: 10.1016/j.bbrc.2008.03.147. Epub 2008 Apr 8.

23.
24.
26.

High cell density induces expression from the carbonic anhydrase 9 promoter.

Kaluzová M, Kaluz S, Stanbridge EJ.

Biotechniques. 2004 Feb;36(2):228-30, 232, 234. No abstract available.

27.

A quantitative single-cell assay for protein kinase B reveals important insights into the biochemical behavior of an intracellular substrate peptide.

Li H, Sims CE, Kaluzova M, Stanbridge EJ, Allbritton NL.

Biochemistry. 2004 Feb 17;43(6):1599-608.

PMID:
14769036
28.
30.

Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase.

Kaluz S, Kaluzová M, Chrastina A, Olive PL, Pastoreková S, Pastorek J, Lerman MI, Stanbridge EJ.

Cancer Res. 2002 Aug 1;62(15):4469-77.

31.

Characterization of the MN/CA 9 promoter proximal region: a role for specificity protein (SP) and activator protein 1 (AP1) factors.

Kaluzová M, Pastoreková S, Svastová E, Pastorek J, Stanbridge EJ, Kaluz S.

Biochem J. 2001 Nov 1;359(Pt 3):669-77.

32.
33.

P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in MaTu cells.

Kaluzová M, Pastoreková S, Pastorek J, Kaluz S.

Biochim Biophys Acta. 2000 Apr 25;1491(1-3):20-6.

PMID:
10760566
34.

Acute effects of interferon on estrogen receptor function do not involve the extracellular signal-regulated kinases p42mapk and p44mapk.

Flint AP, Abayasekara DR, Wheeler-Jones CP, Riley PR, Kaluz S, Kaluzova M, Sheldrick EL, Fisher PA.

J Interferon Cytokine Res. 2000 Feb;20(2):225-33.

PMID:
10714559
35.

Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase IX. Identification and characterization of a proximal silencer element.

Kaluz S, Kaluzová M, Opavský R, Pastoreková S, Gibadulinová A, Dequiedt F, Kettmann R, Pastorek J.

J Biol Chem. 1999 Nov 12;274(46):32588-95.

36.

Co-transfected SV40 origin of replication activates expression from SV40 promoterless constructs.

Flint A, Kaluz S, Kaluzova M, Sheldrick L, Fisher P, Derecka K.

Biotechniques. 1999 Oct;27(4):728-32.

37.

Identification of MaTu-MX agent as a new strain of lymphocytic choriomeningitis virus (LCMV) and serological indication of horizontal spread of LCMV in human population.

Reiserová L, Kaluzová M, Kaluz S, Willis AC, Závada J, Závodská E, Závadová Z, Ciampor F, Pastorek J, Pastoreková S.

Virology. 1999 Apr 25;257(1):73-83.

38.

Inverse PCR-generated internally deleted constructs for direct characterization of promoter regulatory regions.

Kaluz S, Kaluzová M, Pastorek J.

Biotechniques. 1999 Mar;26(3):446-50. No abstract available.

39.

Up-regulation of p53 by antisense expression of HPV18 E6 oncogene does not influence the level of MN/CA IX tumor-associated protein in HeLa cervical carcinoma cells.

Lieskovská J, Kaluzova M, Opavsky R, Kaluz S, Pastorek J, Kettmann R, Pastoreková S.

Int J Oncol. 1998 Nov;13(5):1081-6.

PMID:
9772303
40.

Sequencing analysis of prion genes from red deer and camel.

Kaluz S, Kaluzova M, Flint AP.

Gene. 1997 Oct 15;199(1-2):283-6.

PMID:
9358067
41.

Biology of tick-borne encephalitis virus.

Gresíková M, Kaluzová M.

Acta Virol. 1997 Apr;41(2):115-24. Review.

PMID:
9219644
42.

Application of suppression PCR to the megaprimer method for site-directed mutagenesis.

Kaluz S, Kaluzova M, Flint AP.

Genet Anal. 1996 Dec;13(6):165-9.

PMID:
9117893
43.

Structure of an ovine interferon receptor and its expression in endometrium.

Kaluz S, Fisher PA, Kaluzova M, Sheldrick EL, Flint AP.

J Mol Endocrinol. 1996 Dec;17(3):207-15.

PMID:
8981227
44.

Rapid PCR-mediated bidirectional deletions.

Kaluz S, Kaluzova M, Flint PF.

Trends Genet. 1996 Nov;12(11):453-4. No abstract available.

PMID:
8973150
45.

Heterogeneity in the third intracytoplasmic region of the oxytocin receptor-encoding gene.

Kaluz S, Kaluzova M, Flint AP.

Gene. 1996 Jun 26;172(2):313-4.

PMID:
8682324
46.

Enzymatically produced composite primers: an application of T4 RNA ligase-coupled primers to PCR.

Kaluz S, Kaluzova M, Flint AP.

Biotechniques. 1995 Aug;19(2):182-4, 186. No abstract available.

PMID:
8527131
47.

Nucleotide sequence of the protein E gene of the tick-borne encephalitis virus strain 595 isolated in Slovakia.

Kaluzová M, Kaluz S, Kozuch O, Pastorek J, Labuda M.

Acta Virol. 1995 Jun;39(3):165-9.

PMID:
8578999
48.

Reverted virulence of attenuated tick-borne encephalitis virus mutant is not accompanied with the changes in deduced viral envelope protein amino acid sequence.

Kaluzová M, Elecková E, Zuffová E, Pastorek J, Kaluz S, Kozuch O, Labuda M.

Acta Virol. 1994 Jun;38(3):133-40.

PMID:
7817894
49.

Change in phenotype of tick-borne encephalitis virus following passage in Ixodes ricinus ticks and associated amino acid substitution in the envelope protein.

Labuda M, Jiang WR, Kaluzova M, Kozuch O, Nuttall PA, Weismann P, Elĕckova E, Zuffová E, Gould EA.

Virus Res. 1994 Mar;31(3):305-15.

PMID:
8191785

Supplemental Content

Loading ...
Support Center